Oncoinvent ASA: Key information relating to the reverse share split and change of ISIN

Oncoinvent ASA announced a 100:1 reverse share split with key dates set: public notice 18 Dec 2025, last day including rights 16 Jan 2026, ex-date 19 Jan 2026, record date 20 Jan 2026, and board approval on 8 Jan 2026; par value will rise from NOK 0.50 to NOK 50. Fractional shares will be rounded down, aggregated and sold on the Oslo Stock Exchange with net proceeds donated to charity, and shares will migrate from ISIN NO0013251173 to new ISIN NO0013711713 effective 19 Jan 2026. The company remains a clinical-stage biotech developing Radspherin® with ongoing Phase 2 work; the announcement is procedural and unlikely to materially alter fundamentals but may affect share count, per-share pricing and trading liquidity.

Analysis

Market structure: The 100:1 reverse split (ISIN change to NO0013711713, ex-date 19 Jan 2026) is purely mechanical—market cap unchanged—but concentrates share count and raises nominal price (par NOK0.5 -> NOK50), which typically reduces liquidity and makes the stock more appealing to institutional investors that avoid sub‑NOK100 tickers. Immediate winners are the company (cleaner capital structure) and potential index/ETF eligibility; losers are small retail holders who will lose fractional shares with no compensation and market makers who face wider spreads. Monitor post-split turnover and % free float reduction; a >10% permanent drop in ADTV would materially increase execution costs.

Risk assessment: Tail risks include a negative Phase‑2 readout (binary, high-impact within 6–18 months), regulatory or litigation risk over the uncompensated rounding, and a dilutive capital raise within 3–6 months—reverse splits in small biotech often precede financing. Immediate (days) risk is liquidity shock and price volatility; short term (weeks/months) is fundraising signaling and option repricing; long term (quarters/years) depends on Radspherin® trial outcomes and cash runway. Hidden dependencies: outstanding warrants/options/convertibles and covenants tied to share counts/price may reprice or trigger accelerations after the split.

Trade implications: Do not add new long exposure to Oncoinvent (ISIN NO0013711713) until 30 trading days post-ISIN change and until ADTV returns to >75% of pre-split levels; existing holders should trim 20–30% to manage rounding/dilution risk. Tactical short: if price gaps up >15% on ex-date, establish a 0.5–1.0% NAV short with stop at +20% and target -35% within 3 months, betting on negative signaling/liquidity fade. Options: if liquid, buy 3–6 month puts (size 0.25–0.5% NAV) or sell short‑dated calls on positions if IV spikes >40% above 90‑day realized.

Contrarian angles: The market may over-interpret the split as purely positive institutionalization; historically, many small‑cap biotech reverse splits presage equity raises—treat the split as a red flag for potential dilution. Conversely, if management uses the procedural change and then refrains from raising capital for 6–12 months and the Phase‑2 shows positive signals, the concentrated register can amplify rallies—this creates asymmetric optionality to buy post‑split after a confirmed no‑dilution signal. Watch for legal challenges or unusually high fractional proceeds (would signal many small holders) as an early contrarian entry point.

Key Decisions for Investors

• Avoid establishing new long positions in Oncoinvent (ISIN NO0013711713) until 30 trading days after 19 Jan 2026 and only if 30‑day ADTV ≥ 75% of pre-split ADTV; if these conditions fail, keep exposure ≤0.5% NAV.
• If you hold Oncoinvent, reduce position by 20–30% within 5 trading days of the ISIN change to lock liquidity and cut rounding/dilution exposure; reinvest proceeds into larger radiopharma names (examples: Novartis NVS or Lantheus LNTH) allocating 1–2% NAV each.
• Establish a tactical short of 0.5–1.0% NAV in Oncoinvent only if price gaps up >15% on ex-date (19 Jan 2026); set a stop-loss at +20% and profit target at -35% within a 3‑month horizon, capitalizing on likely post-split liquidity fade and negative signaling.
• Buy 3–6 month put options on Oncoinvent (or equivalent OTC protection if options not listed) size 0.25–0.5% NAV as asymmetric insurance against Phase‑2 failure or a dilutive raise; if IV spikes >40% above 90‑day realized, consider selling 3–6 week calls against any retained long shares to harvest premium.
• Monitor for a declared capital raise or Phase‑2 readout over the next 30–180 days: if a rights issue/private placement is announced, increase short exposure to 1–2% NAV; if management explicitly states no financing need for ≥12 months and subsequent data are positive, consider rebuilding a small long position after >30 days of normalized liquidity.